EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Exercise Limitations in Amyloid Cardiomyopathy Assessed by Cardiopulmonary Exercise Testing—A Multicentre Study

Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D J Capelle, Chiara Arzilli, Emiliano Fiori und 14 weitere

ESC Heart Failure · 01.04.2025 · 12 (2) · 1326-1335

DOI: 10.1002/ehf2.15147 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 14.11.2024. Verfasst von Robin Willixhofer und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Exercise Test, Cardiomyopathies, Exercise Tolerance, Stroke Volume. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: medical scientific fund of the mayor of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction. This study aimed to determine whether cardiac output reduction or ventilation inefficiency plays a predominant role in limiting exercise in patients with amyloid cardiomyopathy.

Methods

We conducted a multicentre prospective study in patients with AL or ATTR cardiomyopathy who underwent cardiopulmonary exercise testing across four centres. Patients were compared with a propensity-score matched HF cohort based on age, gender, left ventricular ejection fraction (LVEF), and peak oxygen consumption (VO2).

Results

Data from 267 amyloid patients aged 77 (72, 81) years, 86% male, with a median N-terminal pro B-type natriuretic peptide (NT-proBNP) of 2187 (1140, 4383) ng/L, exercise parameters of peak VO2 of 14.1 (11.6;16.9) mL/min/kg, a minute ventilation to carbon dioxide production (VE/VCO2) slope of 37.4 (32.5, 42.6) and a LVEF of 50% (44%, 59%) were analysed. We identified 251 amyloid cardiomyopathy–HF matches. Amyloid patients had a signifnicantly higher VE/VCO2 slope [37.4, inter quartile range (IQR): 32.7, 43.1 vs. 32.1, IQR: 28.7, 37.0, P < 0.0001], NT-proBNP (2249, IQR: 1187, 4420 vs. 718, IQR: 405, 2161 ng/L, P < 0.001), peak heart rate (121 ± 28 vs. 115 ± 27 beats/min, P = 0.007) and peak ventilation (51, IQR: 42, 62 vs. 43, IQR: 33, 53 L/min, P < 0.0001) with earlier anaerobic threshold (VO2 at AT: 8.9, IQR: 6.8, 10.8 vs. 10.8, IQR: 8.9, 12.7 mL/min/kg, P < 0.0001) compared with HF. Between amyloid patients, AL patients (n = 27) were younger (63, IQR: 58, 70 vs. 78, IQR: 72, 81 years, P < 0.0001), had lower VE/VCO2 slope (35.0, IQR: 30.0, 38.7 vs. 38.0, IQR: 32.8, 43.1, P = 0.019), higher end-tidal carbon dioxide partial pressure both at AT (35.1 ± 4.8 vs. 31.4 ± 4.7 mmHg, P < 0.001) and peak exercise (32, IQR: 28, 35 vs. 30, IQR: 26, 33 mmHg, P = 0.039) as compared with ATTR (n = 233).

Conclusions

A higher VE/VCO2 slope and an earlier AT, determining functional capacity impairment, was assessed in patients with amyloid cardiomyopathy compared with the matched HF cohort. Additionally, patients with ATTR might display more severe exercise limitations as compared with AL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Exercise TestCardiomyopathiesExercise ToleranceStroke VolumeAmyloidosisVentricular Function, LeftAmyloid Neuropathies, FamilialHumansMaleFemaleAgedProspective StudiesAged, 80 and overOxygen ConsumptionFollow-Up Studies

Stichwörter der Autor:innen

functional capacityheart failurelight chain amyloidosisrestrictive cardiomyopathytransthyretin amyloidosis

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Centro Cardiologico Monzino, IRCCS, Milan, Italy.
  • Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy and Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
  • Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, 'Sapienza' University of Rome, Rome, Italy.
  • Department of Clinical, Internal Medicine, Anestesiological and Cardiological Sciences, 'Sapienza' University of Rome, Rome, Italy.
  • Department of Clinical Science and Community Health, Cardiovascular Section, University of Milan, Milan, Italy.

Förderung

  • medical scientific fund of the mayor of Vienna

Zitieren

APA

Willixhofer, R., Contini, M., Emdin, M., Magrì, D., Bonomi, A., Salvioni, E., Celeste, F., Del Torto, A., Passino, C., Capelle, C. D. J., Arzilli, C., Fiori, E., Capra, N., Kronberger, C., Ermolaev, N., Kammerlander, A., Musumeci, B., Vergaro, G., Castiglione, V., …, & Agostoni, P. (2025). Exercise Limitations in Amyloid Cardiomyopathy Assessed by Cardiopulmonary Exercise Testing—A Multicentre Study. ESC Heart Failure, 12(2), 1326-1335. https://doi.org/10.1002/ehf2.15147

Vancouver

Willixhofer R, Contini M, Emdin M, Magrì D, Bonomi A, Salvioni E, et al. Exercise Limitations in Amyloid Cardiomyopathy Assessed by Cardiopulmonary Exercise Testing—A Multicentre Study. ESC Heart Failure. 2025;12(2):1326-1335. doi:10.1002/ehf2.15147

BibTeX
@article{Willixhofer2025,
  author = {Willixhofer, Robin and Contini, Mauro and Emdin, Michele and Magrì, Damiano and Bonomi, Alice and Salvioni, Elisabetta and Celeste, Fabrizio and Del Torto, Alberico and Passino, Claudio and Capelle, Christophe D J and Arzilli, Chiara and Fiori, Emiliano and Capra, Nicolò and Kronberger, Christina and Ermolaev, Nikita and Kammerlander, Andreas and Musumeci, Beatrice and Vergaro, Giuseppe and Castiglione, Vincenzo and Rettl, René and Tini, Giacomo and Baggiano, Andrea and Fabiani, Iacopo and Sciomer, Susanna and Badr Eslam, Roza and Agostoni, Piergiuseppe},
  title = {Exercise Limitations in Amyloid Cardiomyopathy Assessed by Cardiopulmonary Exercise Testing—A Multicentre Study},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {2},
  pages = {1326--1335},
  doi = {10.1002/ehf2.15147}
}
Kostenlos starten →